KURE vs THNR
KraneShares MSCI All China Health Care Index ETF against Amplify Weight Loss Drug & Treatment ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
9%
2 shared positions
Fee gap
6 bp
THNR is cheaper
1-year return gap
12.2 pts
THNR is ahead
Larger fund
KURE
$110M
Side by side
| KURE | THNR | |
|---|---|---|
| Fund | KraneShares MSCI All China Health Care Index ETF | Amplify Weight Loss Drug & Treatment ETF |
| Issuer | KraneShares | Amplify |
| Category | Single Country | Global |
| Expense ratio | 0.65% | 0.59% |
| Assets | $110M | $5.6M |
| Average daily dollar volume | $1.5M | $18K |
| Listed | Jan 31, 2018 | May 20, 2024 |
| FrenzyCap score | 38 | 22 |
| 1-month return | +5.2% | −4.6% |
| 3-month return | +11.0% | −4.4% |
| Year to date | +9.9% | −2.8% |
| 1-year return | −12.6% | −0.4% |
| 30-day volatility | 29.4% | 19.2% |
| Worst drawdown, 1 year | −29.7% | −13.1% |
| Trailing 12-month yield | 3.82% | 1.69% |
| Holdings | 63 | 21 |
| Top 10 weight | 53.9% | 60.2% |
| Look-through P/E | — | — |
| Holdings vs fair value | — | −1.7% |
| Holdings above 200-day average | — | 59% |
| Net flow, latest 3 reported months | −$3.3M thru Jun 2026 | $0 thru Jun 2026 |
| 30-day implied volatility | 51.2% | — |
| Holdings as of | as of Jun 30, 2026SEC filing | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
12% of KURE · 9% of THNR| Holding | KURE | THNR |
|---|---|---|
| INNOVENT BIOLOGICS, INC. | 8.80% | 5.00% |
| CSPC PHARMACEUTICAL GROUP LIMITED | 3.68% | 4.48% |
Sector mix of the stock holdings
| Sector | KURE | THNR | Gap |
|---|---|---|---|
| Health Care | 1.3% | 66.5% | −65.3% |
More: full overlap table · KURE holdings · THNR holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.